ATE442373T1 - Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden - Google Patents

Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden

Info

Publication number
ATE442373T1
ATE442373T1 AT96924334T AT96924334T ATE442373T1 AT E442373 T1 ATE442373 T1 AT E442373T1 AT 96924334 T AT96924334 T AT 96924334T AT 96924334 T AT96924334 T AT 96924334T AT E442373 T1 ATE442373 T1 AT E442373T1
Authority
AT
Austria
Prior art keywords
delta
analogs
derivatives
domain
protein
Prior art date
Application number
AT96924334T
Other languages
German (de)
English (en)
Inventor
David Ish-Horowicz
Domingo Henrique
Julian Lewis
Spyridon Artavanis-Tsakonas
Grace Gray
Original Assignee
Imp Cancer Res Tech
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Cancer Res Tech, Univ Yale filed Critical Imp Cancer Res Tech
Application granted granted Critical
Publication of ATE442373T1 publication Critical patent/ATE442373T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96924334T 1995-06-28 1996-06-28 Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden ATE442373T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58995P 1995-06-28 1995-06-28
PCT/US1996/011178 WO1997001571A1 (en) 1995-06-28 1996-06-28 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon

Publications (1)

Publication Number Publication Date
ATE442373T1 true ATE442373T1 (de) 2009-09-15

Family

ID=21692156

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924334T ATE442373T1 (de) 1995-06-28 1996-06-28 Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden

Country Status (11)

Country Link
US (5) US6262025B1 (cg-RX-API-DMAC7.html)
EP (1) EP0861261B9 (cg-RX-API-DMAC7.html)
JP (3) JPH11508771A (cg-RX-API-DMAC7.html)
AT (1) ATE442373T1 (cg-RX-API-DMAC7.html)
AU (1) AU723939B2 (cg-RX-API-DMAC7.html)
CA (1) CA2226087C (cg-RX-API-DMAC7.html)
DE (1) DE69638023D1 (cg-RX-API-DMAC7.html)
DK (1) DK0861261T3 (cg-RX-API-DMAC7.html)
ES (1) ES2334953T3 (cg-RX-API-DMAC7.html)
PT (1) PT861261E (cg-RX-API-DMAC7.html)
WO (1) WO1997001571A1 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0861261B9 (en) 1995-06-28 2010-02-24 Imperial Cancer Research Technology Limited Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US6337387B1 (en) 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US6887475B1 (en) 1996-11-07 2005-05-03 Lorantis Limited Notch
ATE342358T1 (de) 1997-04-04 2006-11-15 Millennium Biotherapeutics Inc Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
ES2284205T3 (es) * 1997-05-14 2007-11-01 Asahi Kasei Kabushiki Kaisha Nuevo inhibidor de diferenciacion.
AU737132B2 (en) * 1997-06-18 2001-08-09 Zymogenetics Inc. Mammalian neuro-growth factor like protein
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
WO2000002897A2 (en) * 1998-07-13 2000-01-20 Yale University Delta cleavage products and methods based thereon
EP1100899A2 (en) * 1998-07-27 2001-05-23 Amgen Inc. Delta-related polypeptides
AU6053899A (en) * 1998-09-18 2000-04-10 Nuvelo, Inc. Methods and compositions relating to egf-repeat-containing polypeptides
EP1518930B1 (en) * 1998-10-13 2007-05-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
AU2001288628A1 (en) * 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
WO2003011317A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
WO2004024764A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1654383A1 (en) * 2003-08-08 2006-05-10 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis, and therapy
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2009507796A (ja) * 2005-09-01 2009-02-26 バスジーン セラピューティクス， インコーポレイテッド デルタ様リガンド４のモジュレーターの利用及び同定方法
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
WO2007053648A2 (en) 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
HRP20160082T1 (hr) * 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8148147B2 (en) * 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
KR101711672B1 (ko) 2008-09-26 2017-03-03 온코메드 파마슈티칼스, 인크. 프리즐드 결합 작용제 및 그의 용도
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
EP2506875A4 (en) * 2009-12-01 2013-11-27 Oncomed Pharm Inc METHOD FOR THE TREATMENT OF TUMORS WITH K-RAS MUTATIONS
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2555782A1 (en) 2010-04-09 2013-02-13 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
JP2013523842A (ja) 2010-04-09 2013-06-17 フレッド ハッチンソン キャンサー リサーチ センター 造血機能を提供するための組成物および方法
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
HK1203081A1 (en) 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
CA2868747A1 (en) * 2012-03-29 2013-10-03 Robert J. Fleming Methods and compositions for modulating notch activity
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
AU2014205662B2 (en) 2013-01-08 2019-09-05 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
NZ758715A (en) 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CA2966042A1 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5856441A (en) 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5869282A (en) 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) * 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
WO1993012141A1 (en) 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
WO1994007522A1 (en) 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
US5750652A (en) 1994-01-21 1998-05-12 Yale University Deltex proteins
EP0861261B9 (en) * 1995-06-28 2010-02-24 Imperial Cancer Research Technology Limited Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
CA2238404A1 (en) 1995-11-22 1997-05-29 Yale University Vertebrate deltex proteins, nucleic acids, and antibodies, and related methods and compositions
WO1997045143A1 (en) 1996-05-31 1997-12-04 The National American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
CA2268751A1 (en) 1996-10-21 1998-04-30 Hsc Research And Development Limited Partnership Fringe proteins and notch signalling
DE69733695T2 (de) 1996-11-07 2006-05-18 Lorantis Ltd. Notch-liganden zur verwendung in der immuntherapie
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
ATE342358T1 (de) 1997-04-04 2006-11-15 Millennium Biotherapeutics Inc Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
ES2284205T3 (es) 1997-05-14 2007-11-01 Asahi Kasei Kabushiki Kaisha Nuevo inhibidor de diferenciacion.
US6436650B1 (en) * 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
TW406393B (en) * 1997-12-01 2000-09-21 United Microelectronics Corp Method of manufacturing dielectrics and the inner-lining
WO2000002897A2 (en) 1998-07-13 2000-01-20 Yale University Delta cleavage products and methods based thereon
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
US20070003893A1 (en) * 2005-06-30 2007-01-04 Radek Bures Combination lighter and breath freshener dispenser

Also Published As

Publication number Publication date
US20030073620A1 (en) 2003-04-17
DK0861261T3 (da) 2009-12-14
AU723939B2 (en) 2000-09-07
EP0861261A1 (en) 1998-09-02
PT861261E (pt) 2009-12-16
DE69638023D1 (de) 2009-10-22
US20070134239A1 (en) 2007-06-14
WO1997001571A1 (en) 1997-01-16
JP2012070735A (ja) 2012-04-12
CA2226087A1 (en) 1997-01-16
EP0861261B1 (en) 2009-09-09
JPH11508771A (ja) 1999-08-03
JP2009039101A (ja) 2009-02-26
US20020107194A1 (en) 2002-08-08
AU6481796A (en) 1997-01-30
ES2334953T3 (es) 2010-03-17
US8415303B2 (en) 2013-04-09
US7118890B2 (en) 2006-10-10
US7928071B2 (en) 2011-04-19
US6783956B2 (en) 2004-08-31
EP0861261B9 (en) 2010-02-24
US6262025B1 (en) 2001-07-17
CA2226087C (en) 2012-01-31
EP0861261A4 (en) 2001-08-29
US20070082846A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
ATE442373T1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
PT813545E (pt) Sequências nucleotídicas e proteicas de genes serrate de vertebrado e métodos nelas baseados
US5198423A (en) Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
EP1124846A4 (en) NOGO GENE NUCLEOTIDE AND PROTEIN SEQUENCES AND METHODS BASED ON SUCH SEQUENCES
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
ATE105842T1 (de) Von thrombin abstammende polypeptid- zusammensetzungen und methoden für ihre benutzung.
EA012071B1 (ru) Селективные агонисты рецептора y4 для терапевтического воздействия
BR9714160A (pt) Antìgenos uspa1 e uspa2 de moraxella catarrhalis
JPH06507639A (ja) セレクチンとｂ百日咳毒素の間のアミノ酸シーケンスの相同性−それから誘導されるペプチド、それに対する抗体、薬剤組成物
CA2559838A1 (en) Y2 selective receptor agonists for therapeutic interventions
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
CA2126212A1 (en) A novel molecule which inhibits neuropeptide tyrosine biological function
US7119168B2 (en) Paralytic peptide for use in neuromuscular therapy
ATE69727T1 (de) Zusammensetzung zur behandlung von an haemophilia- a-inhibitor leidenden kranken.
CA2003886A1 (en) Cloning and expression of simian transforming growth factor-beta 1
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
DE69634994D1 (de) Bindegewebe-wachstumsfaktor 3.
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
ATE329027T1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
ATE219513T1 (de) Molekulares klonieren von genomischen und cdna- sequenzen, die für zelluläre rezeptoren für poliovirus kodieren
Frazier et al. Structure of human thrombospondin: complete amino acid sequence derived from cDNA
FI954889A7 (fi) Proteiini, jolla on TPO-aktiviteetti

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0861261

Country of ref document: EP